Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.

Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima STK, Oliveira DC, do Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I, Carvalho LSF, Nadruz W, Muscelli E, Quinaglia T, Sposito AC, EXCEED-BHS3 Trial Investigator

Open source

DOI: 10.1177/2040622320959248
Published: 2020
Container: Therapeutic advances in chronic disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/2040622320959248,
  title = {Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.},
  author = {Breder I and Cunha Breder J and Bonilha I and Munhoz DB and Medorima STK and Oliveira DC and do Carmo HR and Moreira C and Kontush A and Zimetti F and Zanotti I and Carvalho LSF and Nadruz W and Muscelli E and Quinaglia T and Sposito AC and EXCEED-BHS3 Trial Investigator},
  year = {2020},
  journal = {Therapeutic advances in chronic disease},
  doi = {10.1177/2040622320959248},
  url = {https://doi.org/10.1177/2040622320959248}
}

RIS

TY  - JOUR
TI  - Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.
AU  - Breder I
AU  - Cunha Breder J
AU  - Bonilha I
AU  - Munhoz DB
AU  - Medorima STK
AU  - Oliveira DC
AU  - do Carmo HR
AU  - Moreira C
AU  - Kontush A
AU  - Zimetti F
AU  - Zanotti I
AU  - Carvalho LSF
AU  - Nadruz W
AU  - Muscelli E
AU  - Quinaglia T
AU  - Sposito AC
AU  - EXCEED-BHS3 Trial Investigator
PY  - 2020
JO  - Therapeutic advances in chronic disease
DO  - 10.1177/2040622320959248
UR  - https://doi.org/10.1177/2040622320959248
ER  -

APA

I, B., J, C. B., I, B., DB, M., STK, M., DC, O., HR, D. C., C, M., A, K., F, Z., I, Z., LSF, C., W, N., E, M., T, Q., AC, S., & Investigator, E. T. (2020). Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.. Therapeutic advances in chronic disease. https://doi.org/10.1177/2040622320959248

Source records

pubmed · retrieved 2026-09-25T11:45:24.855Z